Triple threat: HPV vaccine plus immunotherapy shows promise against head and neck cancer
NCT ID NCT04369937
First seen Nov 01, 2025 · Last updated Jun 14, 2026 · Updated 30 times
Summary
This study tested a new treatment for a type of head and neck cancer linked to HPV-16. The treatment combined an HPV vaccine (ISA101b), an immunotherapy drug (pembrolizumab), and standard chemo-radiation. The goal was to see if this mix could help control the cancer for longer. The study involved 18 patients with intermediate-risk disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
Conditions
Explore the condition pages connected to this study.